Driehaus Capital Management
http://www.driehaus.com/index.cfmDriehaus Capital Management is an investment management firm serving institutional clients, high net worth individuals and mutual fund investors. The firm specializes in domestic and international equity investing through separately managed accounts and mutual funds. Driehaus Capital Management was formed in 1982.
View Older Stories
-
Alto Neuroscience raises $120 million in private placement financing
-
Korro Bio raises $85 million in oversubscribed private placement
-
Form SCHEDULE 13G PALATIN TECHNOLOGIES Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Definium Therapeutics, Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Andersen Group Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Planet Labs PBC Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Paymentus Holdings, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Korro Bio, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
ALX Oncology prices $150 million stock and warrant offering
-
Form SCHEDULE 13G Planet Labs PBC Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Paymentus Holdings, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Korro Bio, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Apogee Therapeutics, Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Solaris Energy Infrastru Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Precision BioSciences raises $75 million in stock and warrant offering
-
Relmada Therapeutics prices $100 million stock offering at $2.20 per share
-
Maze Therapeutics raises $150 million in oversubscribed private placement
-
Form SCHEDULE 13G/A Blue Foundry Bancorp Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Paymentus Holdings, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Dynamix Corp Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A QUINSTREET, INC Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Septerna, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Surrozen, Inc./DE Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Solaris Energy Infrastru Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G QUINSTREET, INC Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Paymentus Holdings, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Dynamix Corp Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G/A Septerna, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Edgewise Therapeutics Inc. (EWTX) Announces Pricing of $200M Underwritten Offering of Common Stock
-
Form SCHEDULE 13G Korro Bio, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SCHEDULE 13G Septerna, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Olema Pharmaceuticals (OLMA) Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
-
Form SC 13G Apogee Therapeutics, Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Aerovate Therapeutics (AVTE) and Jade Biosciences Announce Merger Agreement
-
GlycoMimetics (GLYC) Enters Acquisition Agreement With Crescent Biopharma
-
Form SC 13G/A Heritage Insurance Holdi Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G/A APPLIED OPTOELECTRONICS, Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Celcuity (CELC) Pricies 3.87M Underwritten Common Stock Offering at $15.50/sh
-
Celcuity Announces Pricing of Underwritten Common Stock Offering
-
Context Therapeutics (CNTX) Announces $100 Million Private Placement
-
Context Therapeutics Announces $100 Million Private Placement
-
Cancer biotech firm Alterome Therapeutics raises $132 million in Goldman Sachs-led round
-
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
-
Mind Medicine (MNMD) Prices 16.67M Share Offering at $6/sh
-
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Crinetics Pharmaceuticals (CRNX) Announces 8.33M Share Offering at $42/sh
-
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
-
Form SC 13G Heritage Insurance Holdi Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC

